Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease

CRAC 通道抑制剂治疗阿尔茨海默病的临床前表征

• 批准号: 10837680
• 负责人: Milton L Greenberg
• 金额: $ 5万
• 依托单位: VIVREON BIOSCIENCES, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10837680
• 关键词: Administrative Supplement; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease therapeutic; Alzheimer' s disease therapy; Biological Assay; Biological Availability; Biological Sciences; Brain; Businesses; Development; Disease; Disease Progression; Ensure; Freedom; Funding; Gliosis; Goals; Grant; Intellectual Property; Investments; Legal patent; Medicine; Neurons; Oral; Pathogenicity; Pharmaceutical Preparations; Pharmacologic Substance; Property; Risk; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Testing; Therapeutic; U-Series Cooperative Agreements; United States National Institutes of Health; candidate selection; design; human model; inhibitor; interest; lead candidate; lead optimization; mouse model; neuroprotection; new chemical entity; novel; novel therapeutics; pre-clinical; programs; reduce symptoms; therapeutic candidate; therapeutic development

Vivreon Biosciences, LLC 4940 Carroll Canyon Rd. Suite 110 San Diego, CA 92121 [e-mail] Vivreon Biosciences – NIA SBIR #PA-20-272 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements; Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp) Notice Number: NOT-OD-21- 062 Project Summary Vivreon Biosciences is pleased to apply for NIA SBIR Supplement #PA-20-272 to develop intellectual property protection for the preclinical candidate in our currently funded SBIR R44AG061995, “Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease”. Supplemental funding is urgently required for intellectual property freedom-to-operate (FTO) analysis and patent filings. The programmatic goal of R44AG061995 is to de-risk our novel Alzheimer’s therapeutic development candidate to make this program an attractive investment opportunity for third-party investors and pharmaceutical partners. To arrive at a highly promising patentable development candidate, our workflow involved rigorous lead optimization and candidate selection studies. Vivreon medicinal chemists designed and synthesized new chemical entities (NCEs) with calculated parameters suitable for a CNS drug, which were then tested in potency, ADME, and DMPK assays. These efforts have yielded a candidate therapeutic that demonstrates drug-like properties appropriate for further development. The Vivreon candidate therapeutic is orally bioavailable, highly brain penetrant, and effective in mouse and human models of AD. TABA supplemental funding is urgently required for technical and business services to support intellectual property protections.

Vivreon生物科学有限责任公司